Clinical Trial Update: A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic, pharmacodynamic, and safety study evaluating a single dose of rivaroxaban in adults with end-stage renal disease on maintenance hemod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: End-Stage Renal Disease | Phase 1 | Status: COMPLETED